[go: up one dir, main page]

CN104884457A - 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用 - Google Patents

吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN104884457A
CN104884457A CN201480003662.2A CN201480003662A CN104884457A CN 104884457 A CN104884457 A CN 104884457A CN 201480003662 A CN201480003662 A CN 201480003662A CN 104884457 A CN104884457 A CN 104884457A
Authority
CN
China
Prior art keywords
compound
alkyl
formula
pharmaceutically useful
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480003662.2A
Other languages
English (en)
Other versions
CN104884457B (zh
Inventor
吕贺军
孙飘扬
桂斌
董庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201480003662.2A priority Critical patent/CN104884457B/zh
Publication of CN104884457A publication Critical patent/CN104884457A/zh
Application granted granted Critical
Publication of CN104884457B publication Critical patent/CN104884457B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明提供了吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物，其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物及其可药用盐，其制备方法以及它们作为促性腺素释放激素(GnRH)受体拮抗剂特别是作为子宫内膜异位症等治疗剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201480003662.2A 2013-10-30 2014-09-30 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用 Active CN104884457B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480003662.2A CN104884457B (zh) 2013-10-30 2014-09-30 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013105259569 2013-10-30
CN201310525956 2013-10-30
PCT/CN2014/087906 WO2015062391A1 (zh) 2013-10-30 2014-09-30 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用
CN201480003662.2A CN104884457B (zh) 2013-10-30 2014-09-30 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN104884457A true CN104884457A (zh) 2015-09-02
CN104884457B CN104884457B (zh) 2016-12-07

Family

ID=53003302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480003662.2A Active CN104884457B (zh) 2013-10-30 2014-09-30 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用

Country Status (22)

Country Link
US (3) US10005781B2 (zh)
EP (1) EP3064498B1 (zh)
JP (1) JP6412563B2 (zh)
CN (1) CN104884457B (zh)
AU (1) AU2014344504C1 (zh)
BR (1) BR112016008799B1 (zh)
CA (1) CA2927641C (zh)
CY (1) CY1122196T1 (zh)
DK (1) DK3064498T3 (zh)
ES (1) ES2747839T3 (zh)
HR (1) HRP20191679T1 (zh)
HU (1) HUE046314T2 (zh)
LT (1) LT3064498T (zh)
MX (1) MX380546B (zh)
PL (1) PL3064498T3 (zh)
PT (1) PT3064498T (zh)
RS (1) RS59457B1 (zh)
RU (1) RU2674977C2 (zh)
SI (1) SI3064498T1 (zh)
SM (1) SMT201900573T1 (zh)
TW (1) TWI675838B (zh)
WO (1) WO2015062391A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018086608A1 (zh) * 2016-11-14 2018-05-17 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶形式及其制备方法
CN115141809A (zh) * 2022-08-30 2022-10-04 南京诺唯赞生物科技股份有限公司 一种检测gnrh结合蛋白生物学活性的方法及试剂盒
CN115260211A (zh) * 2021-04-29 2022-11-01 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884457B (zh) * 2013-10-30 2016-12-07 上海恒瑞医药有限公司 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用
CN108778280B (zh) * 2016-11-07 2021-07-27 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的多晶型及其制备方法
WO2019020102A1 (zh) 2017-07-28 2019-01-31 江苏恒瑞医药股份有限公司 一种嘧啶酮并杂芳基类衍生物的制备方法及其中间体
CN109970662B (zh) * 2017-12-27 2023-06-30 上海科胜药物研发有限公司 一种制备噁拉戈利中间体的方法
CN117203209A (zh) * 2021-04-02 2023-12-08 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶形式及其制备方法
TW202315622A (zh) * 2021-08-30 2023-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種GnRH受體拮抗劑的結晶工藝
CN120752239A (zh) * 2023-02-24 2025-10-03 日本烟草产业株式会社 经取代的吡唑并嘧啶化合物及其医药用途
CN120731207A (zh) * 2023-02-24 2025-09-30 日本烟草产业株式会社 6-烷氧基吡唑并嘧啶化合物及其药学用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
CN101076531A (zh) * 2004-10-12 2007-11-21 解码遗传学公司 用于阻塞性血管疾病的羧酸迫位取代的双环化合物
CN102361873A (zh) * 2009-03-23 2012-02-22 格兰马克药品股份有限公司 作为tpra1调节剂的稠合嘧啶二酮衍生物
CN102807569A (zh) * 2012-08-21 2012-12-05 四川大学 一种镇静催眠的化合物及其制备方法和用途
WO2013071169A1 (en) * 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2013129879A1 (en) * 2012-02-28 2013-09-06 Sk Chemicals Co., Ltd. Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
EP1479684A4 (en) * 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
JP5072166B2 (ja) * 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
JP4039574B2 (ja) * 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
US20090062258A1 (en) * 2005-02-03 2009-03-05 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
AU2006220559A1 (en) 2005-03-07 2006-09-14 Wyeth Quinoxaline dihydrohalide dihydrates and synthetic methods therefor
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
US9227971B2 (en) 2010-01-19 2016-01-05 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
CN102807568B (zh) * 2011-05-31 2015-11-25 正大天晴药业集团股份有限公司 噻二唑衍生物类dpp-iv抑制剂
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
CN104884457B (zh) * 2013-10-30 2016-12-07 上海恒瑞医药有限公司 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
CN101076531A (zh) * 2004-10-12 2007-11-21 解码遗传学公司 用于阻塞性血管疾病的羧酸迫位取代的双环化合物
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
CN102361873A (zh) * 2009-03-23 2012-02-22 格兰马克药品股份有限公司 作为tpra1调节剂的稠合嘧啶二酮衍生物
WO2013071169A1 (en) * 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2013129879A1 (en) * 2012-02-28 2013-09-06 Sk Chemicals Co., Ltd. Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same
CN102807569A (zh) * 2012-08-21 2012-12-05 四川大学 一种镇静催眠的化合物及其制备方法和用途

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018086608A1 (zh) * 2016-11-14 2018-05-17 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶形式及其制备方法
US10787451B2 (en) 2016-11-14 2020-09-29 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of GnRH receptor antagonist and preparation method therefor
AU2017357332B2 (en) * 2016-11-14 2021-10-28 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of GnRH receptor antagonist and preparation method therefor
CN115260211A (zh) * 2021-04-29 2022-11-01 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用
CN115260211B (zh) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用
CN115141809A (zh) * 2022-08-30 2022-10-04 南京诺唯赞生物科技股份有限公司 一种检测gnrh结合蛋白生物学活性的方法及试剂盒

Also Published As

Publication number Publication date
JP6412563B2 (ja) 2018-10-24
CA2927641C (en) 2023-03-14
US20160264578A1 (en) 2016-09-15
ES2747839T3 (es) 2020-03-11
RU2674977C2 (ru) 2018-12-14
RU2016119135A (ru) 2017-12-04
CN104884457B (zh) 2016-12-07
RS59457B1 (sr) 2019-11-29
AU2014344504A1 (en) 2016-05-12
CY1122196T1 (el) 2020-11-25
DK3064498T3 (da) 2019-10-07
BR112016008799B1 (pt) 2023-02-23
JP2016534989A (ja) 2016-11-10
EP3064498B1 (en) 2019-07-17
MX380546B (es) 2025-03-12
EP3064498A4 (en) 2017-03-22
AU2014344504B2 (en) 2018-07-19
PL3064498T3 (pl) 2020-03-31
AU2014344504C1 (en) 2018-11-01
PT3064498T (pt) 2019-10-14
HUE046314T2 (hu) 2020-02-28
TWI675838B (zh) 2019-11-01
BR112016008799A8 (pt) 2020-03-24
MX2016005142A (es) 2016-10-28
LT3064498T (lt) 2019-10-10
HRP20191679T1 (hr) 2019-12-13
SMT201900573T1 (it) 2019-11-13
US10005781B2 (en) 2018-06-26
CA2927641A1 (en) 2015-05-07
TW201536787A (zh) 2015-10-01
US10344034B2 (en) 2019-07-09
RU2016119135A3 (zh) 2018-05-18
US20190270748A1 (en) 2019-09-05
EP3064498A1 (en) 2016-09-07
WO2015062391A1 (zh) 2015-05-07
US10633388B2 (en) 2020-04-28
US20180244679A1 (en) 2018-08-30
SI3064498T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
CN104884457A (zh) 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用
CN106573937B (zh) 作为fshr调节剂的吡唑化合物及其用途
BR112015023279B1 (pt) compostos para inibição de fasn
WO2013064068A1 (zh) 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
CN112673009B (zh) 被取代的三唑并喹喔啉衍生物
CN116768861A (zh) Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途
WO2006083005A1 (ja) 縮合ピリミジン誘導体およびその用途
CN114269738A (zh) 一种mor受体激动剂化合物、制备方法及其用途
WO2020221272A1 (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
WO2018113694A1 (zh) 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用
CN106588914B (zh) 具有取代吡啶并咪唑类衍生物，其制备及其在医药上的应用
CN105658650A (zh) 用作卵泡刺激素受体调节剂的咪唑化合物及其用途
CN101087783B (zh) 作为黄体酮受体调节剂的三取代噻吩类化合物
CN115466266A (zh) mTOR蛋白降解靶向嵌合体及其制备方法和应用
WO2017114453A1 (zh) 喹啉类化合物及其盐的晶型、制备方法、组合物与应用
CN114014890A (zh) 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用
CN114502556A (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
WO2023169453A1 (zh) 一类含杂芳环炔基化合物及其制备方法和用途
WO2025247178A1 (zh) 一类prmt5抑制剂及其组合物和用途
WO2026032385A1 (zh) 多聚adp核糖水解酶抑制剂及其医药用途
CN118772113A (zh) 作为DNA聚合酶Theta抑制剂的含氮杂环化合物
HK40072860B (zh) 一种联苯基氟代双键衍生物及其制备方法和在药学上的应用
HK1220691B (zh) 用作卵泡刺激素受体调节剂的咪唑化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180621

Address after: No. 279, Shanghai, Wen Jing Road, Minhang District, Shanghai

Co-patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Co-patentee after: SUNCADIA PHARMACEUTICALS Co.,Ltd.

Address before: No. 279, Shanghai, Wen Jing Road, Minhang District, Shanghai

Co-patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251217

Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Country or region after: China

Address before: 200245 No. 279, Wen Jing Road, Shanghai, Minhang District

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Country or region before: China

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SUNCADIA PHARMACEUTICALS Co.,Ltd.

TR01 Transfer of patent right